Products from BPS Bioscience require a minimum order value above 400€
Applications: Screen for activators or inhibitors of LAG3 signaling in a cellular contextCharacterize the biological activity of LAG3 and its interactions with ligands
Background: Lymphocyte-activation gene 3 (LAG3, CD223) is a cell surface protein that belongs to the immunoglobulin (Ig) superfamily. LAG3 is expressed on activated T cells, natural killer cells, B cells, and plasmacytoid dendritic cells. Its main ligand is MHC class II, to which it binds with higher affinity than CD4. It negatively regulates cellular proliferation, activation, and homeostasis of T cells in a similar fashion to CTLA-4 and PD-1, and has been reported to play a role in Treg suppressive function. A number of LAG3 antibodies are in preclinical development for treatments for cancer and autoimmune disorders. LAG3 may be a better immune checkpoint inhibitor target than CTLA-4 or PD-1 since antibodies to these two checkpoints are only activating effector T cells, and not inhibiting Treg activity while an antagonist LAG3 antibody can both activate effector T cells (by downregulating the LAG3 inhibiting signal) and inhibit induced (i.e. antigen-specific) Treg suppressive activity.
Description: Recombinant Jurkat T cell expressing firefly luciferase gene under the control of IL-2 response elements with constitutive expression of human LAG3 (lymphocyte-activation gene 3, CD223, GenBank Accession # NM_002286).
Host Cell Line: Jurkat
Mycoplasma Testing: The cell line has been screened using the luminescence-based Lonza MycoAlert™ Mycoplasma Detection Kit (Lonza, USA Catalog #: LT07-318) to confirm the absence of Mycoplasma species.
Storage Stability: Immediately upon receipt, store in liquid nitrogen.
Supplied As: Each vial contains 2 x 10^6 cells in 1 ml of 10% DMSO in FBS
Warnings: Avoid freeze/thaw cycles.
Biosafety Level: BSL-1
English
Deutsch
